Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage...
Day: October 11, 2024
Auron Announces Poster Presentation at 2024 PCF Annual Scientific Retreat
NEWTON, Mass., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Auron Therapeutics, a biotechnology company focused on developing next-generation targeted therapies by...
InnovAge Provides Update on Clinical & Operational Transformations at National PACE Association Annual Conference
Investments in People, Processes and Tools Deliver Enhanced Experience for InnovAge Participants at Company’s 20 CentersDENVER, Oct. 11, 2024 (GLOBE...
Assertio to Participate in the Maxim Group Healthcare Virtual Summit on October 15, 2024
LAKE FOREST, Ill., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical...
Alterity Therapeutics Announces Presentation of New Data Describing Neuroprotection of ATH434 at Neuroscience Meeting
MELBOURNE, Australia and SAN FRANCISCO, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the...
Tourmaline Bio to Showcase Two Poster Presentations at the 2024 Cardiometabolic Health Congress
NEW YORK, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing...
Better Choice Company to Expand into Veterinary Medicine in 2025 Following the Acquisition of SRx Health
TAMPA, Fla., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Better Choice Company (NYSE: BTTR) (“Better Choice” or “the Company”), a pet...
NMD Pharma to Present Data on its Skeletal Muscle Targeted Therapy for Rare Neuromuscular Diseases at the 2024 AANEM Annual Meeting
NMD Pharma to Present Data on its Skeletal Muscle Targeted Therapy for Rare Neuromuscular Diseases at the 2024 AANEM Annual...
Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in The Lancet Gastroenterology & Hepatology
- Treatment with denifanstat achieved statistically significant and clinically meaningful improvements in disease activity, MASH resolution and fibrosis -- Results...
Turnstone Biologics Announces Strategic Restructuring to Prioritize Portfolio and Extend Financial Runway
Realigning resources to focus on clinical advancement of Selected TIL therapyReducing employee headcount by approximately 60%Streamlining operations with cash runway...
Press Release: Sanofi in discussions to sell a controlling stake in Opella
Sanofi in discussions to sell a controlling stake in Opella Paris, October 11, 2024. Sanofi today announces that the company...
NMD Pharma to Present Data on its Skeletal Muscle Targeted Therapy for Rare Neuromuscular Diseases at the 2024 AANEM Annual Meeting
NMD Pharma to Present Data on its Skeletal Muscle Targeted Therapy for Rare Neuromuscular Diseases at the 2024 AANEM Annual...
Sandoz US launches generic paclitaxel in single-dose vial, further expanding US oncology portfolio
MEDIA RELEASE First FDA-approved abbreviated new drug application (ANDA) to reference medicineSingle-dose 100 mg vial for intravenous use, approved for...
FDA approves Roche’s Itovebi, a targeted treatment for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation
Approval is based on Phase III INAVO120 results, showing the Itovebi™ (inavolisib)-based regimen more than doubled progression-free survival compared with...
NMPA Grants Marketing Approval to the First Co-Developed NGS-Based Companion Diagnostic for Lung Cancer in China
GUANGZHOU, China, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), an...
Immatics Announces Pricing of $150 Million Public Offering
Houston, Texas and Tuebingen, Germany, October 10, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in...
Upstream Bio Announces Pricing of Upsized Initial Public Offering
WALTHAM, Mass., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage biotechnology company developing treatments for...
StateHouse Announces Canadian Parent Enters Bankruptcy Proceedings in Canada following Initiation of Receivership Proceedings in the U.S.
SAN DIEGO and TORONTO, Oct. 10, 2024 (GLOBE NEWSWIRE) -- StateHouse Holdings Inc. (“StateHouse” or the “Company”) (CSE: STHZ) (OTCQB:...
CAMP4 Announces Pricing of Initial Public Offering
CAMBRIDGE, Mass., Oct. 10, 2024 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biotechnology company developing a...
Kvantify launches physics-based binding affinity-software for drug discovery with high accuracy and unprecedented speed
Koffee binding affinity is the latest addition to Kvantify's computational drug discovery platform, helping the pharmaceutical and biotech industries design...